Regulatory agencies require sample from both pigs and patients to be archived in cold storage. These samples are for health agency use should they be needed.
While each developer is inventing a unique solution, it is more efficient to centralize this service.
The total number of samples will be surprisingly large, creating a major business opportunity along with a scientific benefit in outcome-improvements.
Regulatory bodies world wide require a sample archive for both pig and patient samples. In the US, the xenotransplantation healthcare teams and even close familial contacts may also be asked to submit samples for archiving. A digital archive of records is also required.
These samples would be used in some cases for patient care, but also in cases of disease outbreaks that may be associated with xenotransplantation.
While the early developers of of xenotransplantation products are tasked with this archiving requirement, it is apparent that a centralized service would be more efficient and likely preferred by regulatory oversight.
A humble, cost conscious early service could grow to include robotic storage and analysis services and serve as a focal point for improving xenotransplantation outcome research in a way that was never possible in the evaluation of transplantation from human donors over the past 50 years of growth in allotransplantation.